Ocular hypotensive effects of medifoxamine

  • Br J Clin Pharmacol. 1992 Sep;34(3):269-71. doi: 10.1111/j.1365-2125.1992.tb04136.x.
S Saleh  1 ,  P Turner
Affiliations
  • 1. Department of Clinical Pharmacology, St Bartholomew's Hospital, London.
PMID: 1389953 DOI: 10.1111/j.1365-2125.1992.tb04136.x
Abstract

Medifoxamine is a novel monoamine re-uptake inhibiting antidepressive drug which preferentially inhibits dopamine reuptake. In human volunteer studies it has been found to reduce significantly intraocular pressure after single oral doses of 300-1000 mg, and to produce a small but statistically significant miosis. Its maximal ocular hypotensive action was less than that of oral timolol 20 mg.

Products